JPWO2021231319A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021231319A5 JPWO2021231319A5 JP2022568632A JP2022568632A JPWO2021231319A5 JP WO2021231319 A5 JPWO2021231319 A5 JP WO2021231319A5 JP 2022568632 A JP2022568632 A JP 2022568632A JP 2022568632 A JP2022568632 A JP 2022568632A JP WO2021231319 A5 JPWO2021231319 A5 JP WO2021231319A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- kit
- polypeptide
- citric acid
- acid monohydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 25
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims 6
- 229960002303 citric acid monohydrate Drugs 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 4
- 239000007979 citrate buffer Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 3
- 229940068977 polysorbate 20 Drugs 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 239000011521 glass Substances 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000003731 mucosal melanoma Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022860P | 2020-05-11 | 2020-05-11 | |
| US63/022,860 | 2020-05-11 | ||
| PCT/US2021/031616 WO2021231319A1 (en) | 2020-05-11 | 2021-05-10 | Il-2 fusion polypeptide compositions and methods of making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526024A JP2023526024A (ja) | 2023-06-20 |
| JPWO2021231319A5 true JPWO2021231319A5 (zh) | 2024-05-17 |
Family
ID=78524880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568632A Pending JP2023526024A (ja) | 2020-05-11 | 2021-05-10 | Ｉｌ－２融合ポリペプチド組成物ならびにその作製及び使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210395325A1 (zh) |
| EP (1) | EP4149514A4 (zh) |
| JP (1) | JP2023526024A (zh) |
| KR (1) | KR20230008759A (zh) |
| CN (1) | CN115867307A (zh) |
| AU (1) | AU2021269585A1 (zh) |
| BR (1) | BR112022022869A2 (zh) |
| CA (1) | CA3172874A1 (zh) |
| IL (1) | IL298064A (zh) |
| MX (1) | MX2022014163A (zh) |
| TW (1) | TW202207971A (zh) |
| WO (1) | WO2021231319A1 (zh) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6234446B2 (ja) * | 2012-06-08 | 2017-11-22 | アルカーメス，インコーポレイテッド | ムチンドメインポリペプチドに連結された活性タンパク質を含む融合ポリペプチド |
| MX2016012447A (es) * | 2014-03-24 | 2017-01-06 | Biogen Ma Inc | Formulaciones de factor ix liofilizadas. |
| CA2966776C (en) * | 2014-12-19 | 2021-05-04 | Alkermes, Inc. | Single chain fc fusion proteins |
| AR111773A1 (es) * | 2017-05-05 | 2019-08-21 | Amgen Inc | Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración |
| BR112022007158A2 (pt) * | 2019-10-18 | 2022-07-05 | Alkermes Pharma Ireland Ltd | Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico |
-
2021
- 2021-05-10 EP EP21804274.5A patent/EP4149514A4/en active Pending
- 2021-05-10 KR KR1020227041366A patent/KR20230008759A/ko active Search and Examination
- 2021-05-10 WO PCT/US2021/031616 patent/WO2021231319A1/en unknown
- 2021-05-10 AU AU2021269585A patent/AU2021269585A1/en active Pending
- 2021-05-10 BR BR112022022869A patent/BR112022022869A2/pt unknown
- 2021-05-10 US US17/315,974 patent/US20210395325A1/en active Pending
- 2021-05-10 IL IL298064A patent/IL298064A/en unknown
- 2021-05-10 JP JP2022568632A patent/JP2023526024A/ja active Pending
- 2021-05-10 CA CA3172874A patent/CA3172874A1/en active Pending
- 2021-05-10 CN CN202180040284.5A patent/CN115867307A/zh active Pending
- 2021-05-10 MX MX2022014163A patent/MX2022014163A/es unknown
- 2021-05-11 TW TW110116904A patent/TW202207971A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2037884C (en) | Stabilized gonadotropin containing preparations | |
| JP5753692B2 (ja) | タンパク質製剤 | |
| US20060159656A1 (en) | Formulations for IL-11 | |
| RU2011151286A (ru) | Лиофилизированные рецептуры для малых модульных иммунофармацевтических средств | |
| CA2272245A1 (en) | Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies | |
| JP2005526084A5 (zh) | ||
| FI3328416T3 (fi) | C-tyypin natriureettisten peptidivarianttien käyttö luuston dysplasian hoidossa | |
| JP2003502364A (ja) | 加水分解型親油性成分を有する両親媒性薬物−オリゴマー結合体およびその製造法および使用法 | |
| US6238664B1 (en) | Process for stabilizing proteins | |
| MX2023004426A (es) | Composiciones adecuadas para su uso en neonatos. | |
| JP2003510369A (ja) | フィブリン溶解剤の薬剤組成物 | |
| CN1642570B (zh) | 含有因子ⅷ的稳定药物组合物 | |
| ES2365832T3 (es) | Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector. | |
| JP2021506922A5 (zh) | ||
| JP2017510585A5 (zh) | ||
| Jin et al. | PEGylation of Lumbrokinase improves pharmacokinetic profile and enhances anti‑thrombotic effect in a rat carotid artery thrombosis model | |
| WO2009086166A1 (en) | Room temperature stable, lyophilized natriuretic peptide formulations | |
| JPWO2021231319A5 (zh) | ||
| KR20220034053A (ko) | 재조합 단백질의 안정적인 제형 | |
| KR900004799B1 (ko) | 안정한 감마 인터페론 제제 및 이의 제조방법 | |
| JP2001524360A (ja) | ０．５ｍｌ未満の容量を投与するための凍結乾燥タンパク質組成物を含む１回量注射器 | |
| US20240041977A1 (en) | Annexin a1 n-terminal peptide formulations and methods | |
| JPH04208228A (ja) | インシュリン様成長因子ｉの乾燥製剤 | |
| JPS5940143B2 (ja) | ペプチド組成物の製法 | |
| US20220288167A1 (en) | A stable lyophilized formulation for hybrid fc fused g-csf |